Bajaj Healthcare applies to Indian patent office for compulsory licence for Baricitinib

Bajaj Healthcare said it has moved the Indian Patent Office requesting to grant a compulsory licence for manufacturing and supply of COVID-19 drug Baricitinib. The company had approached Eli Lilly & Company on two occasions to sign the voluntary licence for manufacturing and supply of Baricitinib and had assured it about manufacturing a high-quality product at an affordable price for the Indian patient population, Bajaj Healthcare said in a filing to BSE.

Eli Lilly & Company declined the applications on both occasions, citing the reason that it is really challenging for them to sign voluntary licensing agreements with all the Indian companies who have requested for the same, it added.

“When all the attempts to get the voluntary licence from the patentee were futile, BHL moved to Indian Patent Office, requesting to grant a compulsory licence for manufacture and supply of COVID-19 drug Baricitinib, so that it can supply the essential medicine in this pandemic situation in India,” Bajaj Healthcare said.

“We have moved the Indian Patent Office to grant a compulsory licence for manufacturing and supply of Covid drug Baricitinib (API and formulation). Currently, the drug Baricitinib is licensed to US pharma giant Eli Lilly & Company, by its originator company INCYTE, providing them with the rights for marketing it across the globe,” Anil Jain, Joint MD, Bajaj Healthcare said.

Considering Bajaj Healthcare’s manufacturing capabilities and strong in-house R&D team, “we can produce ‘Baricitinib at very competitive and affordable prices in India”, he added.

Eli Lilly and Company has already inked voluntary licensing agreements with Sun Pharma, Cipla, Lupin, Torrent Pharmaceuticals, Dr Reddy’s and MSN Laboratories to expedite the availability of Baricitinib for treatment of COVID-19 patients in India.

Eli Lilly and Company has received permission for restricted emergency use by the Central Drugs Standard Control Organization (CDSCO), for Baricitinib to be used in combination with Remdesivir for the treatment of suspected or laboratory-confirmed COVID-19 in hospitalised adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation.